Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PEVIA

Financiado

Cerrado

PAN EBOLA VACCINE INNOVATIVE APPROACH Sofia ref. 116088

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discove... ver más

31/05/2023

ASSISTANCE PUBLIQU...

18M€

Presupuesto del proyecto: 18M€

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-05-31

IMI2-2015-08-01: Ebola and other filoviral haemorrha...

I+D

Cerrada hace 8 años

0% 35% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

ASSISTANCE PUBLIQUE HOPITAUX...

1.30M€ | Lider

EXCELLGENE SA

3.95M€ | Participante

INMI

273.65K€ | Participante

BNI

182.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-112895RB-I00 HACIA EL DESARROLLO DE ANTIVIRALES DE AMPLIO ESPECTRO DIRIGI... 163K€ Cerrado

EbolaVac Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zai... 22M€ Cerrado

REACTION Evaluation of the efficacy and of the antiviral activity of... 3M€ Cerrado

EBO-PEP The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis,... 3M€ Cerrado

FILOVAX Development of Broadly Protective Filovirus Vaccines 50M€ Cerrado

PID2021-122223OB-I00 DESCUBRIMIENTO DE ANTIVIRALES DE AMPLIO ESPECTRO BASADOS EN... 175K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2017-05-31
Fecha Fin: 2023-05-31

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 18M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified. A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores